Edimer Pharmaceuticals; Cmc Biologics

CAMBRIDGE, Massachusetts and BOTHELL, Washington, September 9, 2010 - Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.